Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's Disease

NCT02807675 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT02807675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02807675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's Disease
Lead sponsor
Acorda Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2016
Completion date
November 30, 2016
Enrollment
36 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease